[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

This study is currently recruiting participants.
Verified October 2013 by University of Iowa
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Sarah McGuire, University of Iowa
ClinicalTrials.gov Identifier:
NCT01717391
First received: October 18, 2012
Last updated: October 18, 2013
Last verified: October 2013
  Purpose

[F-18] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.


Condition Intervention Phase
Uterine Cervical Neoplasms
Endometrial Neoplasms
Anus Neoplasms
Rectal Neoplasms
Prostatic Neoplasms
Radiation: Bone marrow sparing IMRT radiation therapy
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging

Resource links provided by NLM:


Further study details as provided by University of Iowa:

Primary Outcome Measures:
  • Changes in FLT uptake as measured by PET/CT scanning [ Time Frame: baseline, weeks 1 and 2 of therapy, 1 month post radiation therapy, and 1 year post radiation therapy ] [ Designated as safety issue: No ]
    Standardized uptake values of the FLT tracer signal in pelvic bone marrow will be used to create patient-specific bone marrow spatial maps to reduce bone marrow dose during radiation therapy planning. Changes in uptake will be assessed in relation to the radiation therapy plan.


Secondary Outcome Measures:
  • Adverse event frequency [ Time Frame: weekly during radiation treatment treatment for up to 8 weeks; then at 1 month, 3 months and 1 year post-radiation ] [ Designated as safety issue: No ]
    Assess grade 2 and higher adverse events. Evaluate the relationship between radiation dose, the bone marrow spatial map, and the adverse event frequency and profile.

  • Blood Cell Counts [ Time Frame: baseline, weekly during radiation treatment for up to 8 weeks, 30 days and 1 year after treatment ] [ Designated as safety issue: No ]
    Blood counts will be recorded to assess the effect of radiation dose on pelvic bone marrow activity.

  • Chemotherapy compliance [ Time Frame: At 24 months ] [ Designated as safety issue: No ]
    The amount of chemotherapy administered will be compared to the amount of chemotherapy prescribed. A secondary comparison against the level of bone marrow suppression (as measured by both the blood cell counts and FLT PET/CT scans) may also be performed. This cannot be assessed until the participant has completed their entire prescribed course of chemotherapy, which will vary based on their tumor type.


Estimated Enrollment: 30
Study Start Date: October 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FLT PET/CT
FLT PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
Radiation: Bone marrow sparing IMRT radiation therapy
A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.

Detailed Description:

Overall survival of pelvic cancer patients depends on control of systemic disease. If local radiation therapy depletes bone marrow function to such an extent that systemic therapies must be withheld, chances of metastatic failure increase significantly. This may be more significant for this group of patients because approximately one third of adult bone marrow is located in the pelvic region. Strategies to minimize toxicities would benefit a range of pelvic cancer patients including gynecologic, anal, rectal, and prostate. New chemoradiation combinations improve outcomes for these disease sites, but come at the cost of higher levels of toxicity. As many as 40% of cervical cancer patients miss at least one chemotherapy cycle due to hematologic toxicity and 36% of anal cancer patients experience grade 3 or 4 hematologic toxicity when undergoing chemoradiation therapy. A clinical trial of concurrent chemoradiation therapy for rectal cancer was terminated due to toxicity, including hematologic toxicities. Concurrent chemoradiation therapy shows promise for advanced stage prostate cancers, but it also increases grade 3 and 4 toxicities. To successfully limit hematologic toxicities for pelvic cancers, it is extremely advantageous to avoid irradiating the highly proliferative compartments of the pelvic bone marrow. However, the complex structure of the pelvis makes it difficult to assess the efficacy of radiation therapy (RT) planning strategies to avoid areas critical to hematopoiesis. Uptake of [18F]fluorothymidine imaged with positron emission tomography (FLT PET/CT) can be an accurate and sensitive tool for identifying and monitoring the effects of chemoradiation on proliferative pelvic bone marrow. Clinically validating the utility of FLT PET/CT imaging for identifying active bone marrow in the design of bone marrow sparing RT-plans and the important bone marrow assessment time points would provide a method to reduce acute and chronic hematologic toxicities for pelvic cancer patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand and willingness to sign a written informed consent document.
  • Recommended to undergo pelvic irradiation with concurrent chemotherapy.
  • At least 18 years of age. Pediatrics would be best served by a protocol designed for their specific needs.
  • Karnofsky Performance Status of at least 60% at time of screening.
  • Life expectancy of greater than 6 months.
  • Subject must have normal organ and marrow function (as defined below) within 30 days of study enrollment:

    • leukocytes at least 3,000 / µL
    • absolute neutrophil count of at least 1500 / µL
    • platelets of at least 100,000 / µL
    • creatinine equal to or less than the upper limit of normal
  • not pregnant (as applicable)

Exclusion Criteria:

  • history of allergic reactions attributed to compounds of similar chemical or biologic composition to FLT
  • an oncology research protocol requiring full pelvic radiation (i.e., 4 field box technique)
  • uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • subjects taking nucleoside analog medications such as those used as antiretroviral agents.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01717391

Contacts
Contact: Sandy Vollstedt, RN, BSN (319) 353-7143 sandy-vollstedt@uiowa.edu
Contact: Jane Hershberger, RN, BSN (319) 384-7912 jane-hershberger@uiowa.edu

Locations
United States, Iowa
Holden Comprehensive Cancer Center Recruiting
Iowa City, Iowa, United States, 52242
Contact: Sandy Vollstedt, RN, BSN    319-353-7143    sandy-vollstedt@uiowa.edu   
Contact: Jane Hershberger, RN, BSN    (319) 384-7912    jane-hershberger@uiowa.edu   
Sub-Investigator: Sudershan K Bhatia, MD, MPH, PhD         
Sub-Investigator: Michael Goodheart, MD         
Sub-Investigator: Yusuf Menda, MD         
Sub-Investigator: John Sunderland, PhD         
Sub-Investigator: John Bayouth, PhD         
Sub-Investigator: Michael Graham, PhD, MD         
Sub-Investigator: Laura Ponto, PhD         
Sub-Investigator: David Dick, PhD         
Sub-Investigator: Brandie Gross, BS, CMD         
Sub-Investigator: Darrin Pelland, RT(T), CMD         
Sub-Investigator: John Buatti, MD         
Sub-Investigator: Mark Smith, MD         
Sub-Investigator: Carryn Anderson, MD         
Sub-Investigator: Wenqing Sun, MD, PhD         
Sub-Investigator: Yusung Kim, PhD         
Sub-Investigator: William Rockey, MD, PhD         
Sub-Investigator: Perrin McNeely, MD         
Sub-Investigator: David Bushnell, MD         
Sub-Investigator: Dean Clermont, CNMT         
Sub-Investigator: Kellie Bodeker, MSHS, CCRC         
Sub-Investigator: Julie Koeppel, B.S.         
Sponsors and Collaborators
University of Iowa
Investigators
Principal Investigator: Sarah McGuire, PhD Department of Radiation Oncology, The University of Iowa
  More Information

Publications:
Responsible Party: Sarah McGuire, Assistant Professor of Radiation Oncology, University of Iowa
ClinicalTrials.gov Identifier: NCT01717391     History of Changes
Other Study ID Numbers: 201204712, R01CA169336
Study First Received: October 18, 2012
Last Updated: October 18, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by University of Iowa:
radiotherapy
Positron-Emission Tomography and Computed Tomography
chemotherapy
bone marrow

Additional relevant MeSH terms:
Rectal Neoplasms
Anus Neoplasms
Neoplasms
Uterine Cervical Neoplasms
Endometrial Neoplasms
Prostatic Neoplasms
Pelvic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Genital Neoplasms, Male
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on April 16, 2014